ScholarIQanswers from OpenAlex

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial

PaperCitations, authors & open-access status

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial have?

ScholarIQcitation count

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial has 113 citations in the OpenAlex counts ScholarIQ stores.

When was Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial published?

ScholarIQyear

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial has 2014 year in the ScholarIQ index.

What is the open-access status of Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial?

ScholarIQoa status

Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial has green oa status in the ScholarIQ index.

What is the DOI of Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial?

ScholarIQdoi

The DOI for Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial is on the source record.

What is the PMID of Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial?

ScholarIQpmid

The PMID for Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial is on the source record.

What is the OpenAlex record for Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial?

ScholarIQopenalex

The OpenAlex for Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial